ACCELERON PHARMA INC
XLRN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XLRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2021.
Tracking 3 pipeline candidates · 3 clinical trials for ACCELERON PHARMA INC.
Similar companies
Run ACCELERON PHARMA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ACCELERON PHARMA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
25.8 months
D/E 0.10
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is ACCELERON PHARMA INC's lead drug candidate?
ACCELERON PHARMA INC's most advanced tracked candidate is ace-1334 (Phase 1) for systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Who is the CEO of ACCELERON PHARMA INC?
Habib J. Dable is the chief executive officer of ACCELERON PHARMA INC (XLRN).
What therapeutic areas does ACCELERON PHARMA INC focus on?
ACCELERON PHARMA INC develops therapies across Oncology, Rare Disease, Immunology, Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.